Osteoblast‐derived extracellular vesicles exert osteoblastic and tumor‐suppressive functions via SERPINA3 and LCN2 in prostate cancer
Molecular Oncology · 2023
DOI: 10.1002/1878-0261.13484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Kagenori Ito und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Integrative Oncology, National Cancer Center Research Institute, Chuo-ku, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Osteoblasts, Serpins, Extracellular Vesicles. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Jikei University Research Fund for Graduate Students.
Abstract (Originalsprache)
Clinically, the osteolytic phenotype is rare in prostate cancer (PCa), and the prognosis is generally worse than that of the osteoblastic phenotype. Osteoblastic prostate cancer (BPCa) is a major type of bone metastasis. Several factors responsible for osteogenesis have been identified, but the molecular mechanism of osteoblastic bone metastasis in PCa is not fully understood. Here, we show the osteogenic and tumor‐suppressive roles of SERPINA3 and LCN2 in BPCa. In a co‐culture of osteoblasts (OBs) and BPCa cells, SERPINA3 and LCN2 were remarkably upregulated in BPCa via OB‐derived extracellular vesicles, while they were not in the co‐culture of OBs and osteolytic prostate cancer (LPCa) cells. In both the co‐culture system and mouse xenograft experiments with intracaudal injection, enhanced expression of SERPINA3 and LCN2 in PCa led to osteogenesis. Additionally, the addition of SERPINA3 and LCN2 to BPCa cells significantly suppressed the proliferative potential. Retrospective analysis also confirmed that high expression levels of SERPINA3 and LCN2 were significantly correlated with a better prognosis. Our results may partially explain how osteoblastic bone metastasis develops and why the prognosis for BPCa is relatively better than that for LPCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Integrative Oncology, National Cancer Center Research Institute, Chuo-ku, Japan.
- Department of Urology, Jikei University School of Medicine, Minato-ku, Japan.
- Department of Molecular and Cellular Medicine, Tokyo Medical University, Shinjuku-ku, Japan.
- Department of Pathology, Jikei University School of Medicine, Minato-ku, Japan.
- Medical Research Institute, Kanazawa Medical University, Kahoku-gun, Japan.
- Department of Urology and Retroperitoneal Surgery, National Cancer Center Hospital, Chuo-ku, Japan.
ORCID-Profile: Takahiro Ochiya, Yusuke Yamamoto
Förderung
- Japan Society for the Promotion of Science
- Jikei University Research Fund for Graduate Students
Zitieren
APA
Ito, K., Yamamoto, T., Hayashi, Y., Sato, S., Nakayama, J., Urabe, F., Shimasaki, T., Nakamura, E., Matui, Y., Fujimoto, H., Kimura, T., Egawa, S., Ochiya, T., & Yamamoto, Y. (2023). Osteoblast‐derived extracellular vesicles exert osteoblastic and tumor‐suppressive functions via SERPINA3 and LCN2 in prostate cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13484
Vancouver
Ito K, Yamamoto T, Hayashi Y, Sato S, Nakayama J, Urabe F, et al. Osteoblast‐derived extracellular vesicles exert osteoblastic and tumor‐suppressive functions via SERPINA3 and LCN2 in prostate cancer. Molecular Oncology. 2023. doi:10.1002/1878-0261.13484
BibTeX
@article{Ito2023,
author = {Ito, Kagenori and Yamamoto, Tomofumi and Hayashi, Yusuke and Sato, Shun and Nakayama, Jun and Urabe, Fumihiko and Shimasaki, Takeo and Nakamura, Eijiro and Matui, Yoshiyuki and Fujimoto, Hiroyuki and Kimura, Takahiro and Egawa, Shin and Ochiya, Takahiro and Yamamoto, Yusuke},
title = {Osteoblast‐derived extracellular vesicles exert osteoblastic and tumor‐suppressive functions via SERPINA3 and LCN2 in prostate cancer},
journal = {Molecular Oncology},
year = {2023},
doi = {10.1002/1878-0261.13484}
}
EUVIMED